In contrast to the mutual exclusivity of many oncogenic drivers in lung cancers, PIK3CA mutations frequently coexist with other oncogenic driver mutations, especially EGFR and KRAS (83, 88–90). The gene discussed is EGFR; the disease is lung cancer.